\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ revealed\\ a\\ non\\-tender\\ thyroid\\ gland\\ with\\ a\\ non\\-tender\\ palpable\\ right\\ thyroid\\ nodules\\.\\ \ \(0\)\
\-\ preoperative\\:\ \(0\)\
\-\ tsh\\ \\=\\ 160\\ mgiu\\/ml\ \(0\)\
\-\ ft4\\ \\=\\ 14\\.3\\ ng\\/dl\ \(0\)\
\-\ raiu\\:\\ 13\\.8\\%\ \(0\)\
\-\ post\\-thyroidectomy\\:\ \(0\)\
\-\ tsh\\ \\=\\ 77\\.25mg\\/ml\ \(0\)\
\-\ ft4\\ \\=\\ 0\\.06ng\\/ml\ \(0\)\
\-\ raiu\\ \\=\\ 2\\.7\\%\ \(0\)\
\-\ thyroid\\ biopsy\\ revealed\\ follicular\\ thyroid\\ cancer\\.\\ \\ the\\ patient\\ underwent\\ thyroidectomy\\.\\ \\ post\\ surgical\\ thyroid\\ scintigraphy\\ revealed\\ residual\\ thyroid\\ avid\\ tissue\\ in\\ the\\ thyroid\\ bed\\ and\\ ablation\\ with\\ high\\ dose\\ i\\ \\(131\\)\\ was\\ administered\\.\ \(0\)\
\-\ preoperative\\ thyroid\\ nuclear\\ scan\\ was\\ performed\\:\\ \\ \ \(0\)\
\-\ i\\ \\(131\\)\\ 7\\.7\\ microcurie\\ was\\ administered\\ 24\\ hours\\ prior\\ to\\ imaging\\ and\\ measurement\\ of\\ the\\ radioactive\\ uptake\\ was\\ 13\\.8\\%\\ \\(normal\\ 8\\%\\ \\-\\ 30\\%\\)\\.\\ on\\ the\\ day\\ of\\ imaging\\ technetium\\ 99m\\-pertechnetate\\ 11\\.0\\ millicurie\\ was\\ administered\\ thyroid\\ imaging\\ revealed\\ a\\ photopenic\\ region\\ in\\ the\\ lateral\\ aspect\\ of\\ the\\ right\\ thyroid\\ gland\\.\\ \\ the\\ findings\\ consistent\\ with\\ a\\ cold\\ thyroid\\ nodule\\.\\ \ \(0\)\
\-\ post\\-thyroidectomy\\ 1\\(123\\)\\ scan\\ demonstrated\\ residual\\ thyroid\\ activity\\ in\\ the\\ thyroid\\ bed\\ with\\ no\\ evidence\\ of\\ extrathyroidal\\ malignancy\\.\\ \\ i\\ \\(131\\)\\ ablation\\ therapy\\ followed\\ with\\ a\\ 185\\ millicurie\\ dose\\.\ \(0\)\
\-\ solitary\\ thyroid\\ nodule\ \(0\)\
\-\ cold\\ thyroid\\ nodule\\ differential\\ diagnosis\ \(0\)\
\-\ malignancy\ \(256\)\
\-\ hematoma\ \(500\)\
\-\ colloid\\ cyst\ \(15\)\
\-\ adenoma\ \(519\)\
\-\ abscess\ \(594\)\
\-\ parathyroid\ \(188\)\
\-\ lymphoma\ \(373\)\
\-\ lymph\\ node\ \(292\)\
\-\ thyroiditis\ \(54\)\
\-\ patient\\ presents\\ for\\ screening\\ carotid\\ ultrasound\\ and\\ a\\ 3cm\\ solitary\\ right\\ thyroid\\ nodule\\ was\\ incidentally\\ discovered\\.\\ \\ the\\ patient\\ denied\\ symptoms\\ of\\ hyperthyroidism\\ or\\ hypothyroidism\\.\ \(0\)\
\-\ pre\\-\\ total\\ thyroidectomy\\:\\ \ \(0\)\
\-\ a\\ very\\ low\\ dose\\ of\\ i\\ \\(131\\)\\,\\ which\\ has\\ a\\ suboptimal\\ imaging\\ \\ gamma\\ emission\\ of\\ 364\\ kev\\,\\ a\\ longer\\ half\\ life\\ of\\ 8\\ days\\,\\ and\\ is\\ a\\ cytotoxic\\ beta\\ minus\\ emitter\\ is\\ used\\ for\\ the\\ pre\\ surgical\\ radioactive\\ uptake\\ \\(raiu\\)\\ measurement\\.\\ thyroid\\ cancers\\ typically\\ have\\ normal\\ raiu\\.\\ \\ technetium\\-99m\\-pertechnate\\ has\\ an\\ optimal\\ imaging\\ gamma\\ emmission\\ of\\ 140\\ kev\\,\\ a\\ shorter\\ half\\ life\\ of\\ 8\\ hours\\,\\ and\\ has\\ no\\ cytotoxic\\ beta\\ emissions\\ \\.\\ \\ \\ \ \(0\)\
\-\ post\\ thyroidectomy\\ and\\ preablation\\:\\ \ \(0\)\
\-\ identifying\\ residual\\ thyroid\\ advid\\ tissue\\ within\\ the\\ thyroid\\ bed\\ and\\ beyond\\ prior\\ to\\ ablation\\.\\ \\ i123\\ has\\ an\\ optimal\\ imaging\\ gamma\\ emission\\ of\\ 159kev\\,\\ a\\ half\\ life\\ of\\ 13\\.27\\ hours\\,\\ and\\ no\\ cytotoxic\\ beta\\ emissions\\.\\ \\ \\ neck\\ and\\ pin\\-hole\\ thyroid\\ as\\ well\\ as\\ whole\\ body\\ anterior\\ and\\ posterior\\ planar\\ images\\ allow\\ identification\\ of\\ iodine\\ avid\\ tissue\\ in\\ and\\ beyond\\ the\\ thyroid\\ bed\\.\\ in\\ preparation\\ for\\ ablation\\,\\ the\\ patient\\ is\\ hypothyroid\\ secondary\\ to\\ hormone\\ replacement\\ medication\\ withdrawl\\ or\\ is\\ placed\\ on\\ thyrogen\\ \\(recombinant\\ tsh\\)\\ which\\ prevents\\ hypothyroid\\ symptoms\\.\\ \\ ablations\\ dose\\ is\\ determined\\ by\\ the\\ presence\\ of\\ absence\\ of\\ metastatic\\ disease\\ and\\ tumor\\ pathology\\.\\ \\ \\ \\ \ \(0\)\
\-\ post\\ ablation\\:\ \(0\)\
\-\ follow\\ up\\ thyroid\\ scintigraphy\\ is\\ performed\\ up\\ to\\ 10\\ days\\ but\\ not\\ earlier\\ than\\ 5\\-6\\ days\\ post\\ ablation\\ to\\ identify\\ metastatic\\ disease\\ and\\ again\\ between\\ six\\ to\\ twelve\\ month\\ to\\ identify\\ residual\\ or\\ recurrent\\ disease\\.\\ \\ \ \(0\)\
\-\ the\\ patients\\ thyroglobulin\\ levels\\ are\\ monitored\\ and\\ they\\ are\\ placed\\ on\\ hormone\\ replacement\\ therapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroid\\:\\ 0\\.5758135254319067\ \(0\)\
\-\ ablation\\:\\ 0\\.21831545306424613\ \(0\)\
\-\ thyroidectomy\\:\\ 0\\.1976639891500428\ \(0\)\
\-\ raiu\\:\\ 0\\.15927062157636893\ \(0\)\
\-\ 131\\:\\ 0\\.1408572346258967\ \(0\)\
\-\ bed\\:\\ 0\\.1383436617085296\ \(0\)\
\-\ dose\\:\\ 0\\.12440580556377812\ \(0\)\
\-\ residual\\:\\ 0\\.12122184684035801\ \(0\)\
\-\ cytotoxic\\:\\ 0\\.11778358305268809\ \(0\)\
\-\ post\\:\\ 0\\.10873219268247657\ \(0\)\
\-\ gamma\\:\\ 0\\.10775575723449791\ \(0\)\
\-\ millicurie\\:\\ 0\\.10652223735837989\ \(0\)\
\-\ nodule\\:\\ 0\\.10514906442966834\ \(0\)\
\-\ imaging\\:\\ 0\\.10501579741268574\ \(0\)\
\-\ beta\\:\\ 0\\.10375774628139721\ \(0\)\
\-\ administered\\:\\ 0\\.1034038904935147\ \(0\)\
\-\ emissions\\:\\ 0\\.10178768460649654\ \(0\)\
\-\ the\\:\\ 0\\.09968176694743683\ \(0\)\
\-\ of\\:\\ 0\\.09776309857427813\ \(0\)\
\-\ tsh\\:\\ 0\\.0965371691342051\ \(0\)\
\-\ and\\:\\ 0\\.09634749125206633\ \(0\)\
\-\ kev\\:\\ 0\\.09582285356587189\ \(0\)\
\-\ half\\:\\ 0\\.09410979565259711\ \(0\)\
\-\ hypothyroid\\:\\ 0\\.09369391321765282\ \(0\)\
\-\ revealed\\:\\ 0\\.08735028367846956\ \(0\)\
\-\ emission\\:\\ 0\\.08466549563039234\ \(0\)\
\-\ optimal\\:\\ 0\\.08299452942514482\ \(0\)\
\-\ life\\:\\ 0\\.08196913856933155\ \(0\)\
\-\ technetium\\:\\ 0\\.08086558907692575\ \(0\)\
\-\ radioactive\\:\\ 0\\.0802342545770319\ \(0\)\
\-\ ft4\\:\\ 0\\.0775063704399654\ \(0\)\
\-\ measurement\\:\\ 0\\.07657172424154864\ \(0\)\
\-\ hours\\:\\ 0\\.07614948651803535\ \(0\)\
\-\ avid\\:\\ 0\\.07529662116131357\ \(0\)\
\-\ preoperative\\:\\ 0\\.07245188414498044\ \(0\)\
\-\ cold\\:\\ 0\\.07097182427117342\ \(0\)\
\-\ identify\\:\\ 0\\.07097182427117342\ \(0\)\
\-\ was\\:\\ 0\\.06964165227338064\ \(0\)\
\-\ beyond\\:\\ 0\\.0694125990511217\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.0691718308542648\ \(0\)\
\-\ hormone\\:\\ 0\\.06782300490928404\ \(0\)\
\-\ days\\:\\ 0\\.06324953494174486\ \(0\)\
\-\ solitary\\:\\ 0\\.06095951180918162\ \(0\)\
\-\ has\\:\\ 0\\.06085006964137716\ \(0\)\
\-\ replacement\\:\\ 0\\.05983587210492363\ \(0\)\
\-\ to\\:\\ 0\\.05828238726077827\ \(0\)\
\-\ is\\:\\ 0\\.054723953596555484\ \(0\)\
\-\ pre\\:\\ 0\\.05444182751168766\ \(0\)\
\-\ gland\\:\\ 0\\.054109131393045344\ \(0\)\
\-\ microcurie\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ emitter\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ emmission\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ preablation\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ advid\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ 159kev\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ thyrogen\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ recombinant\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ ablations\\:\\ 0\\.053261118679189944\ \(0\)\
\-\ tissue\\:\\ 0\\.05241234328239618\ \(0\)\
\-\ placed\\:\\ 0\\.05190390714597302\ \(0\)\
\-\ uptake\\:\\ 0\\.051218387658617415\ \(0\)\
\-\ extrathyroidal\\:\\ 0\\.05089384230324827\ \(0\)\
\-\ withdrawl\\:\\ 0\\.05089384230324827\ \(0\)\
\-\ malignancy\\:\\ 0\\.04986583763647393\ \(0\)\
\-\ minus\\:\\ 0\\.04921423298476809\ \(0\)\
\-\ i123\\:\\ 0\\.04921423298476809\ \(0\)\
\-\ 185\\:\\ 0\\.04516734729034624\ \(0\)\
\-\ 364\\:\\ 0\\.04516734729034624\ \(0\)\
\-\ thyroglobulin\\:\\ 0\\.044479680232884726\ \(0\)\
\-\ patient\\:\\ 0\\.043329105551579095\ \(0\)\
\-\ suboptimal\\:\\ 0\\.042800070914404555\ \(0\)\
\-\ preparation\\:\\ 0\\.042800070914404555\ \(0\)\
\-\ prevents\\:\\ 0\\.042800070914404555\ \(0\)\
\-\ twelve\\:\\ 0\\.042800070914404555\ \(0\)\
\-\ disease\\:\\ 0\\.041940116402206275\ \(0\)\
\-\ shorter\\:\\ 0\\.04149726471257241\ \(0\)\
\-\ in\\:\\ 0\\.041425372479562635\ \(0\)\
\-\ photopenic\\:\\ 0\\.04043279453846287\ \(0\)\
\-\ scan\\:\\ 0\\.03951835998944625\ \(0\)\
\-\ performed\\:\\ 0\\.039406081779716995\ \(0\)\
\-\ 160\\:\\ 0\\.0387531852199827\ \(0\)\
\-\ therapy\\:\\ 0\\.038271170989791645\ \(0\)\
\-\ follicular\\:\\ 0\\.0380655181625212\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.03745037901815055\ \(0\)\
\-\ planar\\:\\ 0\\.03745037901815055\ \(0\)\
\-\ prior\\:\\ 0\\.03726783346460827\ \(0\)\
\-\ 123\\:\\ 0\\.03707357590150253\ \(0\)\
\-\ identifying\\:\\ 0\\.036893917974954345\ \(0\)\
\-\ identification\\:\\ 0\\.036893917974954345\ \(0\)\
\-\ iodine\\:\\ 0\\.03671962378045304\ \(0\)\
\-\ 140\\:\\ 0\\.03655038230969625\ \(0\)\
\-\ allow\\:\\ 0\\.03655038230969625\ \(0\)\
\-\ metastatic\\:\\ 0\\.03653168576012361\ \(0\)\
\-\ symptoms\\:\\ 0\\.03644465298072534\ \(0\)\
\-\ cancers\\:\\ 0\\.03577076969967038\ \(0\)\
\-\ monitored\\:\\ 0\\.03577076969967038\ \(0\)\
\-\ whole\\:\\ 0\\.03495478051139188\ \(0\)\
\-\ 3cm\\:\\ 0\\.03482921821136245\ \(0\)\
\-\ or\\:\\ 0\\.034758109780879995\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.03470629952556085\ \(0\)\
\-\ longer\\:\\ 0\\.03391150245464202\ \(0\)\
\-\ right\\:\\ 0\\.03312544231815633\ \(0\)\
\-\ up\\:\\ 0\\.032948945534728206\ \(0\)\
\-\ with\\:\\ 0\\.032607170667460196\ \(0\)\
\-\ no\\:\\ 0\\.03249071669956116\ \(0\)\
\-\ surgical\\:\\ 0\\.032374130234457614\ \(0\)\
\-\ determined\\:\\ 0\\.031723884005248525\ \(0\)\
\-\ nuclear\\:\\ 0\\.031508948497518695\ \(0\)\
\-\ medication\\:\\ 0\\.030782332516940594\ \(0\)\
\-\ earlier\\:\\ 0\\.030421077803416376\ \(0\)\
\-\ discovered\\:\\ 0\\.03036298357362824\ \(0\)\
\-\ which\\:\\ 0\\.030287759542737273\ \(0\)\
\-\ for\\:\\ 0\\.030282999562651465\ \(0\)\
\-\ on\\:\\ 0\\.03017557655946108\ \(0\)\
\-\ denied\\:\\ 0\\.030080879332831805\ \(0\)\
\-\ six\\:\\ 0\\.029917936052461815\ \(0\)\
\-\ again\\:\\ 0\\.02970751969721689\ \(0\)\
\-\ node\\:\\ 0\\.02862585239160933\ \(0\)\
\-\ incidentally\\:\\ 0\\.02837379503695444\ \(0\)\
\-\ carotid\\:\\ 0\\.028053801427474694\ \(0\)\
\-\ total\\:\\ 0\\.027288803147788882\ \(0\)\
\-\ normal\\:\\ 0\\.027195994163483752\ \(0\)\
\-\ screening\\:\\ 0\\.027054565696522672\ \(0\)\
\-\ as\\:\\ 0\\.026759185597127727\ \(0\)\
\-\ recurrent\\:\\ 0\\.026704473689281496\ \(0\)\
\-\ absence\\:\\ 0\\.026552025813711775\ \(0\)\
\-\ nodules\\:\\ 0\\.026462431903311726\ \(0\)\
\-\ levels\\:\\ 0\\.02640345744306398\ \(0\)\
\-\ pathology\\:\\ 0\\.026145205037508754\ \(0\)\
\-\ an\\:\\ 0\\.025471044988449647\ \(0\)\
\-\ are\\:\\ 0\\.025275073217944914\ \(0\)\
\-\ used\\:\\ 0\\.024932918818236966\ \(0\)\
\-\ activity\\:\\ 0\\.02445157789255301\ \(0\)\
\-\ presence\\:\\ 0\\.023929584510828536\ \(0\)\
\-\ very\\:\\ 0\\.023891299639725964\ \(0\)\
\-\ they\\:\\ 0\\.023796671605183624\ \(0\)\
\-\ 24\\:\\ 0\\.02361189599656425\ \(0\)\
\-\ palpable\\:\\ 0\\.023397617931763152\ \(0\)\
\-\ typically\\:\\ 0\\.02338011140613546\ \(0\)\
\-\ biopsy\\:\\ 0\\.023345255052321146\ \(0\)\
\-\ underwent\\:\\ 0\\.02294244555894331\ \(0\)\
\-\ 30\\:\\ 0\\.02271969945215912\ \(0\)\
\-\ followed\\:\\ 0\\.022490111997936192\ \(0\)\
\-\ cancer\\:\\ 0\\.022183140523904035\ \(0\)\
\-\ body\\:\\ 0\\.02191866141653872\ \(0\)\
\-\ differential\\:\\ 0\\.02163963935711116\ \(0\)\
\-\ between\\:\\ 0\\.02163963935711116\ \(0\)\
\-\ aspect\\:\\ 0\\.021485987807292793\ \(0\)\
\-\ day\\:\\ 0\\.02121438432818025\ \(0\)\
\-\ ultrasound\\:\\ 0\\.020542823272442657\ \(0\)\
\-\ demonstrated\\:\\ 0\\.02046803916954431\ \(0\)\
\-\ neck\\:\\ 0\\.02037327460524674\ \(0\)\
\-\ month\\:\\ 0\\.020259501933054706\ \(0\)\
\-\ region\\:\\ 0\\.019921236394758075\ \(0\)\
\-\ secondary\\:\\ 0\\.01974040691770483\ \(0\)\
\-\ 10\\:\\ 0\\.019474770145215224\ \(0\)\
\-\ cyst\\:\\ 0\\.019212128175033847\ \(0\)\
\-\ low\\:\\ 0\\.01911029265278728\ \(0\)\
\-\ high\\:\\ 0\\.018928085976068796\ \(0\)\
\-\ evidence\\:\\ 0\\.01890367442027159\ \(0\)\
\-\ than\\:\\ 0\\.018879364508998252\ \(0\)\
\-\ patients\\:\\ 0\\.018735593092970654\ \(0\)\
\-\ anterior\\:\\ 0\\.018595277134470792\ \(0\)\
\-\ physical\\:\\ 0\\.01805845520323641\ \(0\)\
\-\ consistent\\:\\ 0\\.01805845520323641\ \(0\)\
\-\ follow\\:\\ 0\\.017954008376213526\ \(0\)\
\-\ tumor\\:\\ 0\\.017420176903682773\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01726480791836963\ \(0\)\
\-\ posterior\\:\\ 0\\.017222035405291786\ \(0\)\
\-\ exam\\:\\ 0\\.01676549338611809\ \(0\)\
\-\ have\\:\\ 0\\.016637416047734093\ \(0\)\
\-\ lateral\\:\\ 0\\.01652828348857977\ \(0\)\
\-\ but\\:\\ 0\\.01646911887251631\ \(0\)\
\-\ findings\\:\\ 0\\.016437098196700438\ \(0\)\
\-\ well\\:\\ 0\\.016126194832528903\ \(0\)\
\-\ presents\\:\\ 0\\.016021175418231916\ \(0\)\
\-\ images\\:\\ 0\\.015405540673341274\ \(0\)\
\-\ within\\:\\ 0\\.015339017865682791\ \(0\)\
\-\ by\\:\\ 0\\.0141430150431686\ \(0\)\
\-\ not\\:\\ 0\\.0131478176467524\ \(0\)\
